AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23557730 — intervention group
Group type: COMPARATOR
Intervention: Attention control (physical activity messages)
Number of subjects: 678
Study 21470751 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative amoxicillin
Number of subjects: 123
Study 21470751 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative amoxicillin
Number of subjects: 123
Study 21470751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 19598023 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus irinotecan, fluorouracil and leucovorin (Group A)
Number of subjects: 62
Study 19598023 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan, fluorouracil and leucovorin (Group B)
Number of subjects: 62
Study 16671837 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional music therapy
Number of subjects: 13
Study 16671837 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvisational music therapy
Number of subjects: 13
Study 16671837 — intervention group
Group type: EXPERIMENTAL
Intervention: Both music therapy treatment groups
Number of subjects: 13
Study 16671837 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13
Study 15448423 — intervention group
Group type: EXPERIMENTAL
Intervention: BMF (human milk fortified with trace elements)
Number of subjects: 62
Study 15448423 — intervention group
Group type: COMPARATOR
Intervention: FM 85 (human milk without trace elements)
Number of subjects: 62
Study 12577332 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined transdermal acupoint electric stimulation (TAES) and isoflurane anesthesia
Number of subjects: 42
Study 12577332 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 42
Study 9225334 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice and protein-rich supplements
Number of subjects: 87
Study 9225334 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 87
Study 8127927 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (36.6 mval)
Number of subjects: 9
Study 8127927 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium sulfate (36 mval)
Number of subjects: 9
Study 8127927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3163370 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental dilation with nasopharyngeal airways
Number of subjects: 44
Study 3163370 — intervention group
Group type: COMPARATOR
Intervention: Nondilated group
Number of subjects: 44
Study 31435716 — intervention group
Group type: EXPERIMENTAL
Intervention: Music offered group (+)MO
Number of subjects: 126
Study 31435716 — intervention group
Group type: COMPARATOR
Intervention: No music offered group (−)MO
Number of subjects: 126
Study 30286418 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear-sparing intensity-modulated radiotherapy (CS-IMRT)
Number of subjects: 110
Study 30286418 — intervention group
Group type: COMPARATOR
Intervention: 3-dimensional conformal radiotherapy (3DCRT)
Number of subjects: 110
Study 27008542 — intervention group
Group type: EXPERIMENTAL
Intervention: D. pteronyssinus subcutaneous allergen immunotherapy (DP-AIT) for 24 months
Number of subjects: 36
Study 27008542 — intervention group
Group type: EXPERIMENTAL
Intervention: D. pteronyssinus subcutaneous allergen immunotherapy (DP-AIT)
Number of subjects: 36
Study 27008542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 26715038 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-management programme (HeLP-Diabetes)
Number of subjects: 350
Study 26715038 — intervention group
Group type: COMPARATOR
Intervention: Simple information website (Control)
Number of subjects: 350
Study 23021996 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 2751
Study 23021996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2751
Study 23021996 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride and Placebo
Number of subjects: 2751
Study 20470379 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 20 mg/day orally for 2 years
Number of subjects: 433
Study 20470379 — intervention group
Group type: COMPARATOR
Intervention: Follow-up alone
Number of subjects: 433
Study 20470379 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 433
Study 18383390 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 539
Study 18383390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 539
Study 22112040 — intervention group
Group type: EXPERIMENTAL
Intervention: New designed forearm orthosis
Number of subjects: 24
Study 22112040 — intervention group
Group type: COMPARATOR
Intervention: Counterforce orthosis
Number of subjects: 24
Study 16100773 — intervention group
Group type: EXPERIMENTAL
Intervention: DLE skin samples
Number of subjects: 70
Study 12426515 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 12
Study 12426515 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study 12426515 — intervention group
Group type: COMPARATOR
Intervention: Orange juice
Number of subjects: 12
Study 9856522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal vaccination (5 injections of 20 microg each)
Number of subjects: 81
Study 9856522 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular vaccination
Number of subjects: 81
Study 9856522 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous vaccination
Number of subjects: 81
Study 7751414 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion (CSI) of octreotide
Number of subjects: 88
Study 7751414 — intervention group
Group type: COMPARATOR
Intervention: Intermittent subcutaneous injection (ISI) of octreotide
Number of subjects: 88
Study 2236455 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (18 mg)
Number of subjects: 150
Study 2236455 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (111 mg)
Number of subjects: 150
Study 2236455 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4.6 capsules)
Number of subjects: 150
Study 2236455 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 150
Study 2236455 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 150
Study 280956 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash (10 ml at 0.1%)
Number of subjects: 18
Study 280956 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine in Broxojet (0.0025%)
Number of subjects: 18
Study 280956 — intervention group
Group type: COMPARATOR
Intervention: Broxojet with placebo
Number of subjects: 18
Study 280956 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine in Broxojet (0.025%)
Number of subjects: 18
Study 12375796 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT‐11, Camptosar)
Number of subjects: 0
Study 12375796 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan in combination with radiation therapy
Number of subjects: 0
Study 31537189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glibenclamide
Number of subjects: 264
Study 29136538 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular coordination training for two weeks
Number of subjects: 30
Study 29136538 — intervention group
Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 30
Study 26376822 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loop excision
Number of subjects: 1515
Study 26376822 — intervention group
Group type: COMPARATOR
Intervention: Punch biopsies with recall for treatment if CIN2/3 confirmed
Number of subjects: 1515
Study 26376822 — intervention group
Group type: COMPARATOR
Intervention: Punch biopsies
Number of subjects: 1515
Study 24989152 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy informed psychotherapy (CBT-ip) only
Number of subjects: 34
Study 24989152 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-ip with medication (sertraline)
Number of subjects: 34
Study 24989152 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (sertraline) only
Number of subjects: 34
Study 24989152 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 34
Study 22248710 — intervention group
Group type: EXPERIMENTAL
Intervention: SC symbol
Number of subjects: 216
Study 22248710 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified SC symbol with serving size information
Number of subjects: 216
Study 22248710 — intervention group
Group type: COMPARATOR
Intervention: No label
Number of subjects: 216
Study 20560365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided technique (US group)
Number of subjects: 37
Study 20560365 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation technique (NS group)
Number of subjects: 37
Study 18029489 — intervention group
Group type: EXPERIMENTAL
Intervention: Almonds (84 g daily for 4 weeks)
Number of subjects: 60
Study 18029489 — intervention group
Group type: COMPARATOR
Intervention: Pork (120 g daily for 4 weeks)
Number of subjects: 60
Study 18029489 — intervention group
Group type: COMPARATOR
Intervention: Pork (same serving as control)
Number of subjects: 60
Study 16148184 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies in lymphocyte supernatant (ALS) assay
Number of subjects: 0
Study 16148184 — intervention group
Group type: COMPARATOR
Intervention: Antibody‐secreting cell (ASC) assay
Number of subjects: 0
Study 12548198 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed drainage system (Group A)
Number of subjects: 72
Study 12548198 — intervention group
Group type: COMPARATOR
Intervention: No drainage (Group B)
Number of subjects: 72
Study 10376852 — intervention group
Group type: EXPERIMENTAL
Intervention: moexipril 15 mg
Number of subjects: 95
Study 10376852 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 95
Study 8777097 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (Group A)
Number of subjects: 60
Study 8777097 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous i.v. infusion of insulin (1.25 u. h‐1) (Group B)
Number of subjects: 60
Study 8777097 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin 10 u. i.v. boluses every 2 h (Group C)
Number of subjects: 60
Study 1984505 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose administration
Number of subjects: 21
Study 1984505 — intervention group
Group type: COMPARATOR
Intervention: Saline administration (Control)
Number of subjects: 21
Study 6190551 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary mustine
Number of subjects: 46
Study 6190551 — intervention group
Group type: COMPARATOR
Intervention: Intracavitary talc
Number of subjects: 46
Study 30287297 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex-guided PTA (DuPTA)
Number of subjects: 142
Study 30287297 — intervention group
Group type: COMPARATOR
Intervention: Conventional PTA
Number of subjects: 142
Study 29427697 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diabetes medications
Number of subjects: 611
Study 29427697 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to medication adherence
Number of subjects: 611
Study 27018561 — intervention group
Group type: EXPERIMENTAL
Intervention: High-anxiety training (HA)
Number of subjects: 0
Study 27018561 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-anxiety training (LA)
Number of subjects: 0
Study 27018561 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 0
Study 24577937 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright sitting posture
Number of subjects: 30
Study 24577937 — intervention group
Group type: COMPARATOR
Intervention: Slumped sitting posture
Number of subjects: 30
Study 22874875 — intervention group
Group type: COMPARATOR
Intervention: Traditional nurse instruction (3 sessions)
Number of subjects: 88
Study 22874875 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 session nurse instruction plus DVD
Number of subjects: 88
Study 21149919 — intervention group
Group type: EXPERIMENTAL
Intervention: fosamprenavir (FPV)/ritonavir
Number of subjects: 27
Study 21149919 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir (LPV)/ritonavir
Number of subjects: 27
Study 21149919 — intervention group
Group type: COMPARATOR
Intervention: Control (tenofovir disoproxil fumarate and lamivudine)
Number of subjects: 27
Study 16962652 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured counseling and patient navigation intervention
Number of subjects: 204
Study 16962652 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 204
Study 16265344 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltitrexed-oxaliplatin (arm A): raltitrexed 3 mg m(‐2) followed by oxaliplatin 130 mg m(‐2) on day 1, repeated every 3 weeks
Number of subjects: 94
Study 16265344 — intervention group
Group type: COMPARATOR
Intervention: Raltitrexed-irinotecan (arm B): CPT‐11 350 mg m(‐2) followed by raltitrexed 3 mg m(‐2), repeated every 3 weeks
Number of subjects: 94
Study 12354086 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total(R) (COL)
Number of subjects: 8
Study 12354086 — intervention group
Group type: EXPERIMENTAL
Intervention: Parodontax(R) (PAR)
Number of subjects: 8
Study 12354086 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexamed(R) (0.1%; CHX)
Number of subjects: 8
Study 12354086 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 8
Study 10200809 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly, six-month progressive walking programme
Number of subjects: 38
Study 8706198 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.65 MAC, 1.3%) with nitrous oxide
Number of subjects: 50
Study 8706198 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (0.65 MAC, 0.8%) with nitrous oxide
Number of subjects: 50
Study 8706198 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 50
Study 8706198 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 50
Study 2357134 — intervention group
Group type: EXPERIMENTAL
Intervention: Long peritoneal lavage (LPL) for 7 days
Number of subjects: 29
Study 2357134 — intervention group
Group type: COMPARATOR
Intervention: Short peritoneal lavage (SPL) for 2 days
Number of subjects: 29
Study 2357134 — intervention group
Group type: EXPERIMENTAL
Intervention: Long peritoneal lavage (LPL) for 7 days among patients with fluid collections on early CT scan
Number of subjects: 29
Study 2357134 — intervention group
Group type: COMPARATOR
Intervention: Short peritoneal lavage (SPL) for 2 days among patients with fluid collections on early CT scan
Number of subjects: 29
Study 2357134 — intervention group
Group type: EXPERIMENTAL
Intervention: Long peritoneal lavage (LPL) for 7 days among patients with five or more positive prognostic signs
Number of subjects: 29
Study 2357134 — intervention group
Group type: COMPARATOR
Intervention: Short peritoneal lavage (SPL) for 2 days among patients with five or more positive prognostic signs
Number of subjects: 29
Study 2357134 — intervention group
Group type: EXPERIMENTAL
Intervention: Long peritoneal lavage (LPL) for 7 days compared to other treatments
Number of subjects: 29
Study 2357134 — intervention group
Group type: COMPARATOR
Intervention: Other treatments (without lavage or lavage for 2 to 4 days)
Number of subjects: 29
Study 395629 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 400 mg at night
Number of subjects: 58
Study 395629 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 58
Study 31282006 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide (3.0 mg)
Number of subjects: 20
Study 31282006 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 29333454 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home VR telerehabilitation (n = 38)
Number of subjects: 76
Study 29333454 — intervention group
Group type: COMPARATOR
Intervention: In-clinic sensory integration balance training (SIBT) (n = 38)
Number of subjects: 76
Study 25296661 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75 mg lozenge
Number of subjects: 402
Study 25296661 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 402
Study 24372992 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg day(‐1)
Number of subjects: 17
Study 24372992 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg day(‐1)
Number of subjects: 17
Study 24372992 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 3.6 g day(‐1)
Number of subjects: 17
Study 24372992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 22738668 — intervention group
Group type: EXPERIMENTAL
Intervention: Next day review (NDR group)
Number of subjects: 291
Study 22738668 — intervention group
Group type: COMPARATOR
Intervention: No next day review (NNDR group)
Number of subjects: 291
Study 19605528 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI) (80 mg/d aglycone isoflavones)
Number of subjects: 29
Study 19605528 — intervention group
Group type: COMPARATOR
Intervention: Milk protein isolate (MPI)
Number of subjects: 29
Study 17478338 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lutein
Number of subjects: 90
Study 17478338 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lutein plus vitamins, minerals, and antioxidants
Number of subjects: 90
Study 17478338 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin placebo
Number of subjects: 90
Study 15669556 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) vaginal cream (0.625 mg/g) applied once daily on days 1-21 of two 28-day cycles
Number of subjects: 150
Study 12508134 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock-wave lithotripsy (SWL)
Number of subjects: 390
Study 12508134 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic ureteroscopic lithotripsy (URS)
Number of subjects: 390
Study 10595633 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 70
Study 10595633 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 70
Study 10595633 — intervention group
Group type: COMPARATOR
Intervention: Pre-menopausal females
Number of subjects: 70
Study 7599569 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY) 4 g/m2 alone
Number of subjects: 35
Study 7599569 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CY) 4 g/m2 followed by GM‐CSF 250 micrograms/m2 or G‐CSF 600 micrograms
Number of subjects: 35
Study 7599569 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY) + GM‐CSF
Number of subjects: 35
Study 7599569 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplant ANC > = 500 x 10(6)/l
Number of subjects: 35
Study 7599569 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplant platelet count > = 50 x 10(6)/l
Number of subjects: 35
Study 7599569 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with NHL
Number of subjects: 35
Study 7599569 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient follow-up
Number of subjects: 35
Study 1971701 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg ipsapirone (IPS)
Number of subjects: 24
Study 1971701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7261629 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate treatment
Number of subjects: 0
Study 7261629 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31778366 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional-assist ventilation (PAV) with flow assist (FA) 40-90% of resistance (Rrs) and volume assist (VA) 40-90% of elastance (Ers)
Number of subjects: 0
Study 31778366 — intervention group
Group type: COMPARATOR
Intervention: Pressure-support ventilation (PSV)
Number of subjects: 0
Study 31778366 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing FA level
Number of subjects: 0
Study 31778366 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing VA level
Number of subjects: 0
Study 28101704 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) - 17.2 kJ gross energy/g diet
Number of subjects: 16
Study 28101704 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein group (HP) - 19.4 kJ gross energy/g diet
Number of subjects: 16
Study 28101704 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat group (HF) - 19.9 kJ gross energy/g diet
Number of subjects: 16
Study 28101704 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate group (HC) - 19.1 kJ gross energy/g diet
Number of subjects: 16
Study 27647058 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 1270
Study 27647058 — intervention group
Group type: COMPARATOR
Intervention: No nicotine patches (usual care)
Number of subjects: 1270
Study 27647058 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 1270
Study 27647058 — intervention group
Group type: COMPARATOR
Intervention: No counseling (usual care)
Number of subjects: 1270
Study 25337269 — intervention group
Group type: EXPERIMENTAL
Intervention: Low oxygen concentration (5%)
Number of subjects: 92
Study 25337269 — intervention group
Group type: COMPARATOR
Intervention: Atmospheric oxygen concentration (20%)
Number of subjects: 92
Study 21559987 — intervention group
Group type: EXPERIMENTAL
Intervention: Vulnamin(®) plus Ca-alginate
Number of subjects: 0
Study 21559987 — intervention group
Group type: COMPARATOR
Intervention: Ca-alginate alone
Number of subjects: 0
Study 19485130 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-hemispheric sensitivity to left-sided manipulations in ratings task
Number of subjects: 3
Study 19485130 — intervention group
Group type: COMPARATOR
Intervention: Children aged 11-13 years
Number of subjects: 3
Study 19485130 — intervention group
Group type: COMPARATOR
Intervention: Children aged 8-10 years
Number of subjects: 3
Study 19485130 — intervention group
Group type: EXPERIMENTAL
Intervention: All age groups
Number of subjects: 3
Study 17312332 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (12 weekly injections, targeting hemoglobin levels between 120 and 140 g/L)
Number of subjects: 300
Study 17312332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 15142880 — intervention group
Group type: EXPERIMENTAL
Intervention: Double induction (arm B)
Number of subjects: 592